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A double-blind, randomized study of zidovudine-experi-
enced, PI- and lamivudine-naive adults with baseline CD4
cell counts of50 cells/mm3 had demonstrated that the HIV
suppression achieved with zidovudine, lamivudine, and in-
dinavir therapy was superior to that achieved with dual-
nucleoside or indinavir-only regimens after 24 weeks of ther-
apy. In a 192-week extension of the study, 371 participants
received open-label indinavir with or without other antiret-
roviral drugs. One hundred and eight subjects were originally
randomized to receive triple therapy. After 216 weeks, the
proportion of subjects with HIV RNA levels of !500 copies/
mL were 34%, according to a general estimating equation
analysis, 92%, according to an observed data analysis, and
24%, according to an intention-to-treat analysis counting
noncompleters as failures; the proportions of subjects with
HIV RNA levels of !50 copies/mL were 31%, 85%, and 22%,
respectively. Hyperbilirubinemia (experienced by 31% of
subjects), nausea (17%), abdominal pain (14%), and ne-
phrolithiasis (13%) were the most common drug-related ad-
verse events during the extension.
Combination antiretroviral therapy including a protease inhib-
itor (PI) is a standard of care for patients with HIV infection
Received 11 February 2003; accepted 5 June 2003; electronically published 18 September
2003.
Reprints or correspondence: Dr. Mark DiNubile, Merck Research Laboratories, PO Box 4,
BL3-4, West Point, PA 19486 (mark_dinubile@merck.com).
Clinical Infectious Diseases 2003; 37:1119–24
 2003 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2003/3708-0018$15.00
[1]. Treatment with PI-containing regimens has resulted in im-
proved rates of patient survival, decreased rates of morbidity,
and reduced health care expenditures [2–9]. Indinavir-based
combination therapy can suppress plasma HIV RNA levels be-
low the limit of quantification of standard assays in the majority
of PI-naive patients [10, 11]. Viral suppression has been main-
tained in some patients for 13 years [12, 13]. Less extensive
data are available for the subset of patients with far-advanced
infection, as indicated by CD4 cell counts of 50 cells/mm3.
A double-blind, randomized study of zidovudine-experienced,
PI- and lamivudine-naive adults with baseline CD4 cell counts
of 50 cells/mm3 had previously demonstrated that the HIV
suppression achieved with triple zidovudine, lamivudine, and
indinavir therapy was superior to that achieved with dual-nu-
cleoside or indinavir-only regimens after 24 weeks of therapy
[14]. Participants completing the initial 24-week study were
eligible to enter a noncomparative extension phase of the study
to assess the long-term efficacy and tolerability of indinavir-
based therapy for advanced HIV infection. In this report, we
update the virological and immunological response data of sub-
jects originally randomized to the triple-therapy arm in the
double-blind study through 216 weeks. We also describe safety
data for all subjects who entered the extension phase of the
study.
METHODS
Study design. The original study was a double-blind, ran-
domized, 24-week study to evaluate the efficacy and safety of
indinavir, zidovudine, and lamivudine (triple) therapy versus
zidovudine and lamivudine (dual nucleoside) therapy versus
indinavir monotherapy in PI- and lamivudine-naive adults with
baseline CD4 cell counts of 50 cells/mm3 who had been
treated with zidovudine for 16 months [14]. There were no
exclusion criteria based on viral RNA levels. Individuals meet-
ing the entry criteria but ineligible for randomization could be
treated with indinavir-containing regimens in a fourth open-
label arm of the study. Participants completing the initial
24-week study were invited to enter an anticipated, noncom-
parative 48-week extension phase of the study and receive open-
label indinavir alone or in combination with other approved
non-PI antiretroviral drugs. There were 3 subsequent exten-
sions. Subjects were instructed to take 800 mg of indinavir
every 8 h on an empty stomach; adequate fluid intake was
stressed. The protocol was approved by the Institutional Review
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Table 1. Selected characteristics and baseline laboratory val-
ues of 108 subjects initially randomized to triple-combination an-
tiretroviral therapy.
Characteristic Value
Male 93 (86)
White 81 (75)
Age in years, median (range) 40 (26–62)
CD4 cell count at baseline,a cells/mm3
Mean  SD 19  15
Median (range) 15 (5–63)
Serum HIV RNA level, log10 copies/mL
Mean  SD 4.83  0.51
Median (range) 4.88 (3.04–6.08)
AIDS-defining illness(es) 62 (57)
NOTE. Data are no. (%) of patients, unless otherwise indicated. These
108 subjects constituted the efficacy cohort for the entire 216 weeks of this
study.
a Four study participants whose CD4 cell counts were50 cells/mm3 when
screened had CD4 cell counts of 150 cells/mm3 (range, 57–63 cells/mm3) on
the first day of study therapy.
Board at each site, and all participants provided written in-
formed consent.
Participants who were initially randomized to receive triple
therapy were observed for 216 weeks for evaluation of efficacy.
All subjects entering the open-label extension study were in-
cluded in the safety evaluation. Only adverse experiences that
developed between week 25 and week 216 of the study were
included in this analysis. Adverse events were considered drug-
related if they were judged by the site investigator as definitely,
probably, or possibly related to indinavir therapy.
Virological and immunological studies. Serum viral RNA
levels were determined by the standard Amplicor PCR assay
(Roche Diagnostics), with a lower limit of quantification of 500
copies/mL. If a signal was detected but the number of copies
was !500 copies/mL, a value of 500 copies/mL was recorded
for that specimen. A value of 250 copies/mL was assigned to
specimens with levels of viral RNA that were undetectable ac-
cording to the standard assay. During the extension phase, test-
ing with the UltraDirect assay (Roche Diagnostics), with a lower
limit of quantification of 50 copies/mL, was performed when-
ever viral RNA levels were !500 copies/mL according to the
standard assay [15]. CD4 cell counts were measured by flow
cytometry.
Statistical analysis. The proportions of subjects with viral
RNA levels below the limit of quantification at scheduled study
visits were analyzed in 3 different ways: first, a “model-based”
intention-to-treat analysis derived from generalized estimating
equations (GEE) that imputed missing data from treatment-
related discontinuations of therapy as failures of treatment sub-
sequent to discontinuation; second, an observed data analysis
in which no missing values were imputed; and, third, a worst-
case intention-to-treat analysis that counted all non-completed
courses of therapy as instances of treatment failure (NCF) [16–
18]. For the GEE analysis, viral RNA measurements that were
missing because of skipped or mistimed visits were imputed as
indicating treatment failure (or success) if the values from visits
immediately preceding and following the missing measurement
both indicated treatment failure (or success); other intermit-
tently missing values were left as missing. In the NCF calcu-
lations, viral RNA measurements missing because of skipped
or mistimed visits were imputed as indicating treatment failure
unless the values immediately before and after the missing value
both indicated treatment success, in which case the absent value
was left as missing.
Indinavir was the only protocol-mandated drug administered
during the extension phases. Participants were not forced to
withdraw from the study if another protease inhibitor or un-
licensed antiretroviral agent was added to their indinavir-
containing regimen. However, if subjects stopped receiving in-
dinavir, their participation in the study was discontinued. All
subjects with viral RNA measurements were counted in the
intention-to-treat analyses. Participants no longer taking in-
dinavir, whether alone or in combination with other drugs,
were subsequently counted as having experienced treatment
failure in the NCF analysis, and they were not included in the
observed data thereafter. These participants were also excluded
from the GEE model after stopping indinavir unless the dis-
continuation of indinavir was prompted by virological failure
and/or a drug-related adverse event, under which conditions
they were counted as having experienced treatment failure.
Changes in baseline viral RNA levels and CD4 cell counts
were summarized over time using both observed data and a
mixed-effects model for repeated measurements in which par-
ticipants with treatment-related discontinuations had their
missing values imputed by carrying forward the last observed
data.
RESULTS
Participant characteristics. The majority of the 465 partic-
ipants enrolled in the 4 treatment arms of the original study
were middle-aged white men with prior AIDS-defining illnesses
who had been treated with zidovudine for 12 years before entry
into the study [14]. A total of 371 subjects completed the parent
study and entered the open-label extension phase. Efficacy was
evaluated over the entire 216 weeks of the study in all 108 of
the participants who were initially randomized to triple therapy
(table 1). Ninety-one (84%) of these 108 subjects completed
the randomized phase, entered the extension phase, and con-
tinued to receive their original triple combination regimen.
Three subjects receiving triple therapy (3%) declined to enter
the extension phase after completing the initial 24 weeks.
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Figure 1. Proportions of subjects with viral RNA (vRNA) levels !500 copies/mL (A) and !50 copies/mL (B). The proportions of the 108 subjects
initially randomized to triple-therapy whose vRNA levels fell below the limit of quantification for the standard (A) and ultrasensitive (B) vRNA assays
are shown at each scheduled study visit, based on observed data, a general estimating equation model (GEE model), and the analysis counting all
noncompleted courses of therapy as instances of treatment failure (NCF) (for definitions, see Methods). Bars represent 95% CIs. aNo. of patients with
observed data at the corresponding time.
Twenty-eight subjects who received triple therapy (26%) com-
pleted all 216 weeks of the study.
Seventy-seven subjects receiving triple-therapy did not com-
plete all 216 weeks of the study. Reasons for not completing
the entire study included the following: reaching clinical end
points, 4 (4%) of 108 subjects; experiencing clinical adverse
events, 14 (13%) (9 of whom [8%] experienced drug-related
clinical adverse events); experiencing laboratory adverse events,
5 (5%) (4 of whom [4%] experienced drug-related laboratory
adverse events); lack of efficacy, 26 (24%); and withdrawal of
consent, 18 (17%). Four (4%) of the 108 participants discon-
tinued the study for miscellaneous reasons related to relocation,
investigator discretion, or personal preference. Six subjects
(6%) were lost to follow-up during the extension period.
A total of 5 subjects, 2 of whom were initially randomized
to triple therapy, added ritonavir to their regimens during the
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Figure 2. Changes from baseline viral RNA (vRNA) levels (A) and CD4 cell counts (B) over time. The mean changes from baseline in vRNA levels
(A) and CD4 cell counts (B) at each scheduled study visit are shown for the 108 subjects initially randomized to triple therapy, computed using either
the observed data or the mixed-effects model (for definitions, see Methods). Bars represent 95% CIs. aNo. of patients with observed data at the
corresponding time.
extension phases. One participant who was randomized to tri-
ple therapy developed Pneumocystis carinii pneumonia and died
during the first 24 weeks of the study, and 3 additional subjects
died during the extension periods. In 2 of these cases, death
was attributed to infections.
Virological and immunological responses. The propor-
tions of the 108 subjects receiving triple therapy with viral RNA
levels of !500 copies/mL and !50 copies/mL over the duration
of the study are shown in figure 1, which displays the results
of all 3 analyses. At week 216, the GEE analysis showed that
34% of the 108 subjects had viral RNA levels of !500 copies/
mL and 31% had !50 copies/mL. According to the NCF analy-
sis, 26 (24%) of the subjects had RNA levels of !500 copies/
mL and 24 (22%) of the subjects had RNA levels of !50 copies/
mL at week 216. According to the observed data of the 26
participants with viral RNA measurements at week 216, there
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Table 2. Clinical and laboratory adverse events developing during the 192-week
extension phase in all 371 subjects entering the extension phase.
Type of adverse experience
No. (%) of subjects, by clinical
or laboratory adverse experience
Clinical Laboratorya
Developed
adverse
experience
Discontinued
therapy
Developed
adverse
experience
Discontinued
therapy
Any 360 (97.0) 54 (14.6) 272 (73.3) 12 (3.2)
Drug-related 253 (68.2) 33 (8.9) 234 (63.1) 11 (3.0)
Serious 125 (33.7) 21 (5.7) 11 (3.0) 1 (0.3)
Serious and drug-related 39 (10.5) 4 (1.1) 5 (1.3) 1 (0.3)
NOTE. Eighteen (4.8%) of 371 subjects died during the extension phase.
a Laboratory test results were available for 369 (99%) of the 371 subjects during the extension
phase.
were 24 (92%) who had RNA levels of !500 copies/mL and 22
(85%) who had RNA levels of !50 copies/mL. Only 2 partic-
ipants with viral suppression at the completion of the study
had changed antiretroviral therapy from their original triple-
drug regimen. Figure 2 displays the mean changes in viral RNA
levels (shown in panel A) and CD4 cell counts (shown in panel
B) from baseline values. The model-based estimates were a
decrease of 1.3 log10 viral RNA copies/mL and an increase of
204 CD4 cells/mm3 at week 216.
Adverse events. Of the 465 participants enrolled in the
original 24-week study, 371 (80%) entered the first extension
(weeks 25–72); 251 (54%) entered the next extension (weeks
73–120); 119 (26%) entered the third extension (weeks 121–
168); and 80 (17%) entered the final extension (weeks 169–
216). Of the 371 subjects (86% men; 84% white; median age
[range] in years, 39 [20–66]) who entered any extension phase,
97% experienced 1 clinical adverse event and 73% experi-
enced 1 laboratory adverse event between week 25 and week
216 (table 2). Overall, 68% experienced drug-related clinical
adverse events and 63% experienced drug-related laboratory
adverse events, which were considered serious in 11% and 1%
of cases, respectively. Thirty-four persons (9%) discontinued
the extension because of drug-related adverse events, including
5 (1%) with serious drug-related adverse events. Eighteen par-
ticipants (5%) died during the extension period, but no death
was directly attributable to drug toxicity.
The most frequent drug-related clinical adverse events were
diarrhea (experienced by 38% of subjects), fatigue (34%), nau-
sea (33%), abdominal pain (32%), and fever (30%). Nephrol-
ithiasis was documented in 13% of subjects; 20 subjects (5%)
discontinued the study because of nephrolithiasis. The most
common drug-related laboratory adverse events were hyper-
bilirubinemia (31% of subjects) and abnormal urinalysis results
(28%) (including hematuria, pyuria, and proteinuria, each doc-
umented in 10% of subjects).
DISCUSSION
This study is unique in 2 respects. Only zidovudine-experienced
subjects with advanced HIV infection, characterized by a CD4
lymphocyte count of 50 cells/mm3, were enrolled. Further-
more, participants with far advanced HIV were observed for
up to 4 years. Our results indicate that triple-combination an-
tiretroviral therapy containing indinavir can result in long-term
virological and immunological benefits for some PI-naive pa-
tients with advanced HIV infection [12, 13].
Marked reductions of viral RNA levels and elevations in CD4
cell counts were maintained in a sizable minority of subjects
for up to 216 weeks. According to the GEE analysis, at week
216, 34% of subjects initially randomized to triple-therapy had
viral RNA levels that were suppressed to !500 copies/mL, and
the viral RNA levels of 31% of subjects were !50 copies/mL.
According to a worst-case intention-to-treat analysis in which
noncompletion of therapy was regarded as treatment failure,
viral RNA levels were suppressed to !50 copies/mL in 22% of
subjects. During the 216-week study, lack of efficacy led to study
discontinuation by 22% of the subjects receiving triple therapy,
and adverse experiences led to study discontinuation by 18%
of the subjects receiving triple therapy. In the large majority of
participants still under observation at the end of the study, viral
RNA levels remained !50 copies/mL.
Adverse experiences observed among subjects receiving pro-
longed indinavir therapy appeared to be comparable in type
and frequency to those observed during the initial 24 weeks of
the study [14] and were consistent with the established adverse-
event profile for indinavir-containing regimens [10, 11]. The
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open-label design of the extension phase and the paucity of
restrictions on other medications may have affected the re-
porting and attribution of adverse experiences. Overall, con-
stitutional and gastrointestinal complaints, isolated hyperbili-
rubinemia, and suspected or documented nephrolithiasis were
the most important adverse events. Five percent of subjects
left the study during the extension phases as a result of
nephrolithiasis.
In summary, we investigated the effects of zidovudine, la-
mivudine, and indinavir combination therapy in an open-label,
noncomparative study of PI-naive subjects at a late stage of
HIV infection who had been pretreated with zidovudine. Our
results indicate that some patients with advanced HIV infection
can benefit from combination antiretroviral therapy for
prolonged periods. The frequency and severity of drug-related
adverse experiences reported in this study were similar to
the established adverse-event profile for indinavir-containing
regimens.
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